Innoveren Scientific Inc. (IVRN)
OTCMKTS: IVRN · Delayed Price · USD
0.0036
0.00 (0.00%)
Jun 3, 2024, 12:00 AM EDT - Market closed
Innoveren Scientific Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | 0.45 | 1.61 | 2.15 | 8.35 | 7.88 |
| Revenue Growth (YoY) | - | -71.86% | -25.07% | -74.23% | 5.88% | - |
| Cost of Revenue | 0 | 0.12 | 0.7 | 0.77 | 2.05 | 2.37 |
| Gross Profit | -0 | 0.34 | 0.91 | 1.38 | 6.29 | 5.52 |
| Selling, General & Admin | 2.09 | 3.39 | 6.1 | 7.32 | 18.71 | 9.01 |
| Research & Development | - | - | - | 1.15 | 0.11 | - |
| Depreciation & Amortization | - | - | - | - | 0.83 | 0.1 |
| Operating Expenses | 2.09 | 3.39 | 6.1 | 8.48 | 19.65 | 9.1 |
| Operating Income | -2.09 | -3.06 | -5.19 | -7.09 | -13.36 | -3.59 |
| Interest Expense | -0.44 | -0.37 | -0.18 | -1.46 | -0.3 | -0.18 |
| Interest & Investment Income | 0 | 0.51 | - | - | - | - |
| Other Non Operating Income (Expenses) | 0.26 | -3.14 | -0.04 | 0.59 | 0.7 | -0.02 |
| EBT Excluding Unusual Items | -2.27 | -6.06 | -5.41 | -7.96 | -12.96 | -3.79 |
| Impairment of Goodwill | - | - | - | - | -12.56 | - |
| Gain (Loss) on Sale of Assets | - | -0.01 | -0.09 | - | - | - |
| Asset Writedown | - | - | - | - | -2.94 | -0.61 |
| Other Unusual Items | -0.2 | -2.2 | 0.7 | 1.5 | -1.34 | - |
| Pretax Income | -3.26 | -10.3 | -4.8 | -6.46 | -29.81 | -4.39 |
| Net Income | -3.26 | -10.3 | -4.8 | -6.46 | -29.81 | -4.39 |
| Preferred Dividends & Other Adjustments | - | - | - | 0.32 | 3.39 | - |
| Net Income to Common | -3.26 | -10.3 | -4.8 | -6.78 | -33.2 | -4.39 |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 |
| Shares Change (YoY) | 152.30% | 101.58% | 30.72% | 15.69% | 186.30% | - |
| EPS (Basic) | -5.51 | -35.06 | -32.93 | -60.82 | -344.46 | -130.54 |
| EPS (Diluted) | -5.51 | -35.06 | -32.93 | -60.82 | -344.46 | -130.54 |
| Free Cash Flow | -0.92 | -1.91 | -4.82 | -7.26 | -12.31 | -3.56 |
| Free Cash Flow Per Share | -1.55 | -6.51 | -33.06 | -65.12 | -127.76 | -105.64 |
| Gross Margin | - | 74.07% | 56.27% | 64.34% | 75.41% | 69.98% |
| Operating Margin | - | -674.36% | -322.23% | -329.77% | -160.06% | -45.48% |
| Profit Margin | - | - | -297.81% | - | - | -55.74% |
| Free Cash Flow Margin | - | -422.03% | -298.95% | -337.57% | -147.50% | -45.11% |
| EBITDA | -2.08 | -3.04 | -5.18 | -7.01 | -12.53 | -3.49 |
| EBITDA Margin | - | - | - | - | -150.06% | -44.27% |
| D&A For EBITDA | 0.01 | 0.01 | 0.02 | 0.08 | 0.83 | 0.1 |
| EBIT | -2.09 | -3.06 | -5.19 | -7.09 | -13.36 | -3.59 |
| EBIT Margin | - | - | - | - | -160.06% | -45.48% |
| Advertising Expenses | - | - | - | - | 4.91 | 1.88 |
Source: S&P Capital IQ. Standard template.